Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors

David R. Shook, Brandon M. Triplett, Ashok Srinivasan, Christine Hartford, Mari H. Dallas, Asha Pillai, Joseph Laver, Wing Leung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Children with relapsed or refractory solid tumors face dismal prognoses, and novel therapies are desperately needed. Allogeneic hematopoietic cell transplantation (HCT) offers potential for cell-based therapy, but the toxicity of myeloablation limits this approach in heavily pretreated patients. We sought to determine the feasibility of HCT in a cohort of 24 children with incurable solid tumors using human leukocyte antigen-matched sibling or unrelated donors and a minimal conditioning regimen. Before stem cell infusion, all patients received 3 daily doses of 30 mg/m2 fludarabine followed by 2 Gy of total body irradiation. Hematopoietic cell recovery was rapid and reliable. Median time to neutrophil engraftment was 13.5 days for sibling donors and 12 days for unrelated donors. Donor lymphocyte infusions were used safely in 4 patients, all of whom had either improved chimerism or apparent tumor response. Graft-versus-host disease was comparable across donor sources and did not affect survival. Relapse remains a substantial barrier, although objective graft-versus-tumor effect was observed in several patients. Four patients with detectable disease before HCT achieved a complete response for at least 30 days after HCT, and two remain long-term survivors. Three patients were in complete response before HCT and remained in remission for 3, 6, and 74 months after HCT. Early disease response was associated with improved survival. Allogeneic HCT using this conditioning regimen offers a potential platform for novel immunotherapies.

Original languageEnglish (US)
Pages (from-to)291-297
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Cell Transplantation
Neoplasms
Unrelated Donors
Tissue Donors
Siblings
Transplantation Conditioning
Chimerism
Survival
Whole-Body Irradiation
Graft vs Host Disease
HLA Antigens
Cell- and Tissue-Based Therapy
Conditioning (Psychology)
Immunotherapy
Survivors
Neutrophils
Stem Cells
Lymphocytes
Transplants
Recurrence

Keywords

  • Allogeneic stem cell transplantation
  • Graft-versus-tumor
  • Pediatric soild tumor
  • Reduced-intensity transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors. / Shook, David R.; Triplett, Brandon M.; Srinivasan, Ashok; Hartford, Christine; Dallas, Mari H.; Pillai, Asha; Laver, Joseph; Leung, Wing.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 2, 01.02.2013, p. 291-297.

Research output: Contribution to journalArticle

Shook, David R. ; Triplett, Brandon M. ; Srinivasan, Ashok ; Hartford, Christine ; Dallas, Mari H. ; Pillai, Asha ; Laver, Joseph ; Leung, Wing. / Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 2. pp. 291-297.
@article{b2406be4ea3a40fe89d55e0077d3b3c6,
title = "Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors",
abstract = "Children with relapsed or refractory solid tumors face dismal prognoses, and novel therapies are desperately needed. Allogeneic hematopoietic cell transplantation (HCT) offers potential for cell-based therapy, but the toxicity of myeloablation limits this approach in heavily pretreated patients. We sought to determine the feasibility of HCT in a cohort of 24 children with incurable solid tumors using human leukocyte antigen-matched sibling or unrelated donors and a minimal conditioning regimen. Before stem cell infusion, all patients received 3 daily doses of 30 mg/m2 fludarabine followed by 2 Gy of total body irradiation. Hematopoietic cell recovery was rapid and reliable. Median time to neutrophil engraftment was 13.5 days for sibling donors and 12 days for unrelated donors. Donor lymphocyte infusions were used safely in 4 patients, all of whom had either improved chimerism or apparent tumor response. Graft-versus-host disease was comparable across donor sources and did not affect survival. Relapse remains a substantial barrier, although objective graft-versus-tumor effect was observed in several patients. Four patients with detectable disease before HCT achieved a complete response for at least 30 days after HCT, and two remain long-term survivors. Three patients were in complete response before HCT and remained in remission for 3, 6, and 74 months after HCT. Early disease response was associated with improved survival. Allogeneic HCT using this conditioning regimen offers a potential platform for novel immunotherapies.",
keywords = "Allogeneic stem cell transplantation, Graft-versus-tumor, Pediatric soild tumor, Reduced-intensity transplantation",
author = "Shook, {David R.} and Triplett, {Brandon M.} and Ashok Srinivasan and Christine Hartford and Dallas, {Mari H.} and Asha Pillai and Joseph Laver and Wing Leung",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.bbmt.2012.10.001",
language = "English (US)",
volume = "19",
pages = "291--297",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors

AU - Shook, David R.

AU - Triplett, Brandon M.

AU - Srinivasan, Ashok

AU - Hartford, Christine

AU - Dallas, Mari H.

AU - Pillai, Asha

AU - Laver, Joseph

AU - Leung, Wing

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Children with relapsed or refractory solid tumors face dismal prognoses, and novel therapies are desperately needed. Allogeneic hematopoietic cell transplantation (HCT) offers potential for cell-based therapy, but the toxicity of myeloablation limits this approach in heavily pretreated patients. We sought to determine the feasibility of HCT in a cohort of 24 children with incurable solid tumors using human leukocyte antigen-matched sibling or unrelated donors and a minimal conditioning regimen. Before stem cell infusion, all patients received 3 daily doses of 30 mg/m2 fludarabine followed by 2 Gy of total body irradiation. Hematopoietic cell recovery was rapid and reliable. Median time to neutrophil engraftment was 13.5 days for sibling donors and 12 days for unrelated donors. Donor lymphocyte infusions were used safely in 4 patients, all of whom had either improved chimerism or apparent tumor response. Graft-versus-host disease was comparable across donor sources and did not affect survival. Relapse remains a substantial barrier, although objective graft-versus-tumor effect was observed in several patients. Four patients with detectable disease before HCT achieved a complete response for at least 30 days after HCT, and two remain long-term survivors. Three patients were in complete response before HCT and remained in remission for 3, 6, and 74 months after HCT. Early disease response was associated with improved survival. Allogeneic HCT using this conditioning regimen offers a potential platform for novel immunotherapies.

AB - Children with relapsed or refractory solid tumors face dismal prognoses, and novel therapies are desperately needed. Allogeneic hematopoietic cell transplantation (HCT) offers potential for cell-based therapy, but the toxicity of myeloablation limits this approach in heavily pretreated patients. We sought to determine the feasibility of HCT in a cohort of 24 children with incurable solid tumors using human leukocyte antigen-matched sibling or unrelated donors and a minimal conditioning regimen. Before stem cell infusion, all patients received 3 daily doses of 30 mg/m2 fludarabine followed by 2 Gy of total body irradiation. Hematopoietic cell recovery was rapid and reliable. Median time to neutrophil engraftment was 13.5 days for sibling donors and 12 days for unrelated donors. Donor lymphocyte infusions were used safely in 4 patients, all of whom had either improved chimerism or apparent tumor response. Graft-versus-host disease was comparable across donor sources and did not affect survival. Relapse remains a substantial barrier, although objective graft-versus-tumor effect was observed in several patients. Four patients with detectable disease before HCT achieved a complete response for at least 30 days after HCT, and two remain long-term survivors. Three patients were in complete response before HCT and remained in remission for 3, 6, and 74 months after HCT. Early disease response was associated with improved survival. Allogeneic HCT using this conditioning regimen offers a potential platform for novel immunotherapies.

KW - Allogeneic stem cell transplantation

KW - Graft-versus-tumor

KW - Pediatric soild tumor

KW - Reduced-intensity transplantation

UR - http://www.scopus.com/inward/record.url?scp=84872619760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872619760&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.10.001

DO - 10.1016/j.bbmt.2012.10.001

M3 - Article

C2 - 23063628

AN - SCOPUS:84872619760

VL - 19

SP - 291

EP - 297

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -